These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 22041864

  • 1. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study.
    Ardawi MS, Al-Sibiany AM, Bakhsh TM, Rouzi AA, Qari MH.
    Osteoporos Int; 2012 Jun; 23(6):1789-97. PubMed ID: 22041864
    [Abstract] [Full Text] [Related]

  • 2. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.
    van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE.
    Eur J Endocrinol; 2010 Nov; 163(5):833-7. PubMed ID: 20817762
    [Abstract] [Full Text] [Related]

  • 3. Clinical, Biochemical, and Radiological Profile of Normocalcemic Primary Hyperparathyroidism.
    Palermo A, Naciu AM, Tabacco G, Falcone S, Santonati A, Maggi D, D'Onofrio L, Briganti SI, Castellitto D, Casini A, Pedone C, Lelli D, Fabbri A, Bilezikian JP, Napoli N, Pozzilli P, Manfrini S, Cesareo R.
    J Clin Endocrinol Metab; 2020 Jul 01; 105(7):. PubMed ID: 32271382
    [Abstract] [Full Text] [Related]

  • 4. Sclerostin and DKK1 in primary hyperparathyroidism.
    Viapiana O, Fracassi E, Troplini S, Idolazzi L, Rossini M, Adami S, Gatti D.
    Calcif Tissue Int; 2013 Apr 01; 92(4):324-9. PubMed ID: 23430197
    [Abstract] [Full Text] [Related]

  • 5. Does Baseline PTH Influence Recovery of Bone Mineral Density, Trabecular Bone Score and Bone Turnover Markers? A Prospective Study Following Curative PArathyroidectomy in Primary Hyperparathyroidism.
    Shetty S, Cherian KE, Shetty S, Kapoor N, Jebasingh FK, Cherian A, Hephzibah J, Chandramohan A, John RA, Asha HS, Paul MJ, Manipadam MT, Abraham DT, Thomas N, Paul TV.
    Endocr Pract; 2020 Dec 01; 26(12):1442-1450. PubMed ID: 33471736
    [Abstract] [Full Text] [Related]

  • 6. Marked and sustained increase in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism; a six-year longitudinal study with or without parathyroidectomy in a Japanese population.
    Nomura R, Sugimoto T, Tsukamoto T, Yamauchi M, Sowa H, Chen Q, Yamaguchi T, Kobayashi A, Chihara K.
    Clin Endocrinol (Oxf); 2004 Mar 01; 60(3):335-42. PubMed ID: 15008999
    [Abstract] [Full Text] [Related]

  • 7. Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy.
    Marini F, Giusti F, Cioppi F, Maraghelli D, Cavalli T, Tonelli F, Brandi ML.
    Cells; 2021 Jul 26; 10(8):. PubMed ID: 34440663
    [Abstract] [Full Text] [Related]

  • 8. The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy.
    Alonso S, Ferrero E, Donat M, Martínez G, Vargas C, Hidalgo M, Moreno E.
    J Endocrinol Invest; 2012 Jul 26; 35(7):640-4. PubMed ID: 21946027
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of changes in bone density and biochemical parameters after parathyroidectomy in primary hyperparathyroidism.
    Nakaoka D, Sugimoto T, Kobayashi T, Yamaguchi T, Kobayashi A, Chihara K.
    Endocr J; 2000 Jun 26; 47(3):231-7. PubMed ID: 11036865
    [Abstract] [Full Text] [Related]

  • 10. Predictors of bone mineral density improvement in patients undergoing parathyroidectomy for primary hyperparathyroidism.
    Sharma J, Itum DS, Moss L, Li C, Weber C.
    World J Surg; 2014 Jun 26; 38(6):1268-73. PubMed ID: 24744114
    [Abstract] [Full Text] [Related]

  • 11. Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism.
    Evenepoel P, Claes K, Viaene L, Bammens B, Meijers B, Naesens M, Sprangers B, Kuypers D.
    Transplantation; 2016 Oct 26; 100(10):2188-93. PubMed ID: 27379556
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
    Rajput S, Dutta A, Rajender S, Mithal A, Chattopadhyay N.
    Front Endocrinol (Lausanne); 2023 Oct 26; 14():1098841. PubMed ID: 36817591
    [Abstract] [Full Text] [Related]

  • 14. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
    Cejka D, Jäger-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M.
    Nephrol Dial Transplant; 2012 Jan 26; 27(1):226-30. PubMed ID: 21613383
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Relationship Between Osteoporosis and Serum Sclerostin Levels in Kidney Transplant Recipients.
    Basir H, Altunoren O, Erken E, Kilinc M, Sarisik FN, Isiktas S, Gungor O.
    Exp Clin Transplant; 2024 Jul 26; 22(7):514-521. PubMed ID: 31526333
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.